Vitamin C for Patients Hospitalized With COVID-19

To the Editor The recently published REMAP-CAP and LOVIT-COVID studies tested the hypothesis that the administration of high-dose vitamin C (ascorbic acid) increases the number of days patients are alive and free from organ support. However, these studies were terminated early when statistical triggers for harm and futility were met. In addition, the earlier LOVIT study found harm from high-dose vitamin C and a higher risk of death or persistent organ dysfunction at 28 days. The dose of vitamin C given to the 1476 patients with critical illness in the 3 studies was 50 mg/kg of body weight administered 4 times daily. For a patient weighing 60 kg, this is 12 g of vitamin C daily.
Source: JAMA - Category: General Medicine Source Type: research